Intravitreal Bevacizumab for Non-Arteritic Anterior Ischemic Optic Neuropathy
NCT00813059
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Non-arteritic Anterior Ischemic Optic Neuropathy
Interventions
DRUG:
Intra-vitreal injection of bevacizumab (1.25mg/0.05ml)
Sponsor
Mount Sinai Hospital, Canada